TFA Therapeutics (RAJAF) Income towards Parent Company (2020 - 2023)

TFA Therapeutics has reported Income towards Parent Company for 4 years, with the latest figure at $57616.0 in Q4 2023.

• On a quarterly basis, Income towards Parent Company rose 116.85% year-over-year to $57616.0 in Q4 2023; TTM through Dec 2023 was -$669359.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$154822.0, up 31.57% from the prior year.
• Income towards Parent Company was $57616.0 for Q4 2023 at TFA Therapeutics, up from -$341873.0 in the prior quarter.
• The five-year high for Income towards Parent Company was $57616.0 in Q4 2023, with the low at -$371626.0 in Q4 2021.
• Average Income towards Parent Company over 4 years is -$167339.8, with a median of -$177674.5 recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: Income towards Parent Company plunged 2657.69% in 2021, then jumped 116.85% in 2023.
• Over 4 years, Income towards Parent Company stood at -$13476.0 in 2020, then slumped by 2657.69% to -$371626.0 in 2021, then grew by 8.01% to -$341873.0 in 2022, then soared by 116.85% to $57616.0 in 2023.
• The last three Income towards Parent Company figures came in at $57616.0 (Q4 2023), -$341873.0 (Q4 2022), and -$371626.0 (Q4 2021), per Business Quant data.